[A26-64] Aficamten (obstructive hypertrophic cardiomyopathy) – Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2026
Project no.:
A26-64
Commission:
Commission awarded on 01.06.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Indication:
Adults with symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM)
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A26-64